Clinical trial NCT04093206: Compare Effects of EpiCor and Vitamin C to Vitamin C Alone on the Common Cold or Influenza in Healthy Children
Official title: A Double-blind, Randomized, Controlled Study to Compare the Effects of Syrup With EpiCor and Vitamin C to Syrup With Vitamin C Alone on the Common Cold or Influenza in Generally Healthy Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Signs and Symptoms, Respiratory
Lead sponsor: Cargill
Sponsor class: INDUSTRY
Collaborators: name: Clinres Farmacija d.o.o.
name: PharmaLinea d.o.o.
name: Diagnostic Laboratory Medicare PLUS d.o.o.
name: Embria Health Sciences
First posted: 2019-09-17
Enrollment: 221
Sex: ALL
Minimum age (years): 1
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of the clinical study is to evaluate efficacy of regular daily, 12 weeks, consumption of EpiCor syrup containing EpiCor and vitamin C in non-vaccinated children 1-6 years old on preventing episodes of the common cold and flu as well as on the severity of symptoms of the common cold and flu in case of their occurrence. Additionally, the study aims to assess the effect of EpiCor on the use of prescription drugs and changes of a selected biochemical marker. This is a double-blind, randomized, controlled multi-center clinical trial.

Detailed description: This is a double-blind, randomized, controlled multi-center clinical trial aiming to evaluate the effects of daily consumption of EpiCor with vitamin C, primarily on the incidence and, secondary, on the duration and severity of the common cold and influenza in children, compared to the effects of daily consumption of vitamin C alone. Healthy children aged 1-6 years old are included in the study after parents have provided informed consent for study participation. Children are divided in 3 age groups (1-2 year old, 3-4 years old, 5-6 years old) and randomized in one of the two groups (intervention or control) at a 1:1 ratio. Children eligible for participation are included in the study for 12 weeks. During this period, they visit the investigational center 3 times. During visit 1 (day 0) caregivers get familiarized with the purpose, course and procedures of the trial, provide written informed consent upon which investigator assesses child's suitability for participation and, for eligible children, a study participant number is provided and a randomization number is assigned; in addition, the investigator collects demographic information, data on vital signs, medical history, collects a sample for determination of salivary secretory immunoglobulin A (sIgA), provides caregivers with a Study Dairy and clear instructions regarding completion, consumption, storage and return of unused syrup, taking medication and other food supplements during the study, monitoring adverse events and measures to be taken in the event of serious adverse events, determines the daily dose of syrup to be taken based on child's age, supplies the caregiver with enough syrup and sets a date for next visit. Between visits, children take a prescribed dose of syrup once daily. Six weeks (visit 2) and 12 weeks (visit 3) after the first visit, children and caregivers visit the investigational center again. During these 2 visits, the investigator collects data on vital signs, reviews concomitant medication and the taking of other food supplements, collects sample for determination of salivary SIgA, reviews the Study Dairy, supplies the caregiver with new syrup and provides the same clear instructions as in visit 1. Caregivers are asked to complete the Study Dairy on daily basis and, each time a caregiver marks that a symptom is present, the Investigator receives a notification and reviews the symptoms and consequently confirms the episode of a common cold/flu. The Canadian Acute Respiratory Illness and Flu Scale (CARIFS) is used to assess the severity of symptoms of the common cold and flu in participating children and, in case of occurrence of cold/flu symptoms, caregivers are asked to complete the form twice a day for the first seven days, once on day 10 and once on day 14.

Eligibility criteria: Inclusion Criteria:

* Generally healthy male and female children
* 1-6 years of age
* Children attending kindergarten
* Signed informed consent by child's parent or legal guardian and willingness to participate in all study activities

Exclusion Criteria:

* Immune dysfunction and/or taking an immunosuppressive medication
* Child who has received flu vaccination
* Child who is still breastfed
* Child taking other food supplements
* Unable or unwilling to comply with study protocol, including ingesting investigational product, and completing subject dairy
* Current participation in another clinical study
* Severe co-morbidity or concomitant disease
* Concurrent disease or condition, which in the judgment of the investigator, would make the child inappropriate for participation in the study
* High risk of complications from influenza
* Allergies to yeast-derived products
* Severe environmental allergies requiring medication or need for allergy shots

Primary outcomes:
measure: Incidence of the common cold an influenza
timeFrame: Number of episodes of common cold and/or influenza during 12 weeks of product consumption
Secondary outcomes:
measure: Duration of the common cold and influenza
timeFrame: Duration of common cold and influenza during 12 weeks of product consumption
measure: Severity of common cold and influenza
timeFrame: Severity of common cold and influenza symptoms during the 12 weeks of product consumption
measure: Use of prescription drugs
timeFrame: Number of prescription drugs during the 12 weeks of product consumption
measure: Change of salivary secretory immunoglobulin A (sIgA) levels
timeFrame: Change of salivary sIgA levels after 6 and 12 weeks of product consumption
measure: Safety of investigational product consumption
timeFrame: Safety of investigational product consumption during the 12 weeks study period
Other outcomes:
Locations:
city: Domžale
country: Slovenia
facility: Zdravstveni dom Domzale
city: Ilirska Bistrica
country: Slovenia
facility: Zasebna pediatricna ordinacija Ivan Kauzlaric
city: Ivančna Gorica
country: Slovenia
facility: ZD Ivancna Gorica
city: Kocevje
country: Slovenia
facility: Zdravstveni dom Kocevje
city: Lenart v Slov Goricah
country: Slovenia
facility: Ambulanta za otroke in solarje Pedenjped d.o.o.
city: Lenart v Slov Goricah
country: Slovenia
facility: Zasebna otroska in solska ambulanta Mojca Ivankovic Kacjan
city: Lenart V Slov. Goricah
country: Slovenia
facility: Zasebna ambulanta Moj pediater Matjaz Homsak
city: Ljubljana
country: Slovenia
facility: Clinres Farmacija d.o.o.
city: Ljubljana
country: Slovenia
facility: Zdravstveni dom Ljubljana
city: Lucija
country: Slovenia
facility: Zasebna pediatricna ambulanta Vesna Lazar Daneu
city: Maribor
country: Slovenia
facility: Pediatrinja Suzana Skorjanc Antolic Zdravstvena Dejavnost d.o.o.
city: Maribor
country: Slovenia
facility: Zdravstveni dom Dr. Adolfa Droca Maribor
city: Maribor
country: Slovenia
facility: Zdravstveni dom Dr. Adolfa Drolca Maribor
city: Sempeter pri Gorici
country: Slovenia
facility: Zdravstveni dom Nova Gorica
city: Sentilj v Slovenskih goricah
country: Slovenia
facility: Pediatrija Sentilj
city: Slovenske Konjice
country: Slovenia
facility: Zasebna pediatricna ambulanta Damir Dabranin
city: Tolmin
country: Slovenia
facility: Zdravstveni dom Tolmin
city: Trebnje
country: Slovenia
facility: Zadravstveni dom Trebnje
city: Trebnje
country: Slovenia
facility: Zdravstveni dom Trebnje
city: Trzic
country: Slovenia
facility: Zasebna Otroska in Solska Ordinacija
city: Zagorje ob Savi
country: Slovenia
facility: Zdravstveni dom Zagorje
Study officials:
affiliation: University of Ljubljana
name: Alojz Ihan
role: PRINCIPAL_INVESTIGATOR
References: